Donald C Moore

26PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|May 18, 2026
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.

|Sep 18, 2025
ONS/ASCO Guideline on the Management of Antineoplastic Extravasation.

Tanya Thomas, Caroline Clark, Chelsea Backler

|Jun 17, 2025
Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated, HR-positive, HER2-negative invasive breast cancer: A systematic review.

Chris Larck, Joseph B Elmes, R Wesley Haynes

|Nov 11, 2024
Omidubicel for Hematopoietic Cell Transplants: Considerations for Patients and Treatment Outcomes.

Allison L Morse, Hana Kurz, Donald C Moore

|Nov 04, 2024
A second chance for avatrombopag in chemotherapy-induced thrombocytopenia.

Hanny Al-Samkari, Donald C Moore

|Oct 07, 2024
B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice.

Matthew R Peery, Hailey Hill, Amanda Sharps

Pageof 5

Frequent Collaborators

4 joint publications

Justin R Arnall

2 joint publications

Chris Larck

1 joint publications

Alana M Ciolek

1 joint publications

Kathryn Dane